-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986218 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986218 in Colorectal CancerDrug Details:BMS-986218 is under development for the treatment of advanced solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986218 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986218 in Non-Small Cell Lung CancerDrug Details:BMS-986218 is under development for the treatment of advanced solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986218 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986218 in MelanomaDrug Details:BMS-986218 is under development for the treatment of advanced solid tumors including prostate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1495 in Transitional Cell Cancer (Urothelial Cell Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1495 in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details:TPST-1495 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986218 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986218 in Solid Tumor Drug Details:BMS-986218 is under development for the treatment of advanced solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1495 in Endometrial Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1495 in Endometrial Cancer Drug Details:TPST-1495 is under development for the treatment of microsatellite-stable colorectal cancer...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1495 in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1495 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:TPST-1495 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1495 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1495 in Non-Small Cell Lung Cancer Drug Details:TPST-1495 is under development for the treatment of microsatellite-stable...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Colorectal CancerDrug Details:TPST-1120 is under development for the treatment of solid tumors including castration...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Pancreatic CancerDrug Details:TPST-1120 is under development for the treatment of solid tumors including castration...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Hepatocellular Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Hepatocellular CarcinomaDrug Details:TPST-1120 is under development for the treatment of solid tumors including castration...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Bile Duct Cancer (Cholangiocarcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Bile Duct Cancer (Cholangiocarcinoma)Drug Details:TPST-1120 is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Non-Small Cell Lung CancerDrug Details:TPST-1120 is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Transitional Cell Cancer (Urothelial Cell Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Transitional Cell Cancer (Urothelial Cell Cancer)Drug Details:TPST-1120 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Gastroesophageal (GE) Junction Carcinomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Gastroesophageal (GE) Junction CarcinomasDrug Details:TPST-1120 is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Leiomyosarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in LeiomyosarcomaDrug Details:TPST-1120 is under development for the treatment of solid tumors including castration resistant...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Liposarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in LiposarcomaDrug Details:TPST-1120 is under development for the treatment of solid tumors including castration resistant...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Drug Details:TPST-1120 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TPST-1120 in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TPST-1120 in Triple-Negative Breast Cancer (TNBC)Drug Details:TPST-1120 is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AUM-001 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AUM-001 in Solid Tumor Drug Details: AUM-001 (ETC-206) is under investigation for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.